A single infusion of Celularity‘s PNK-007 — an investigational cell therapy derived from placental stem cells — is safe and leads to good response…
Nektar Therapeutics is launching a first-in-human Phase 1 clinical trial to assess the safety and efficacy of…
Health Canada has approved Darzalex (daratumumab), in combination with standard Revlimid (lenalidomide) and dexamethasone, for people newly diagnosed with multiple myeloma who…
A combination of Darzalex (daratumumab), Kyprolis (carfilzomib), and dexamethasone increases the time to disease progression or death in  multiple myeloma patients who…
GBR 1342, an investigational bispecific antibody developed by Glenmark Pharmaceuticals, was granted orphan drug designation by the U.S Food and Drug Administration (FDA) for…
Evomela, an injectable formulation of melphalan, is now available in China as a high-dose conditioning therapy for people with multiple myeloma who will…
Sleep apnea can drive the development of aggressive multiple myeloma in mice resistant to the cancer, a study found, suggesting that the sleep disorder is…
Treatment with Kyprolis (carfilzomib) once a week is as safe and effective as the twice-weekly regimen used for the initial treatment of multiple myeloma patients, a…